Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Oncotarget · 2016 · PMC5008347 · PMID 26959885

Europe PMC DOI

hedged sentences

0.1600

closest p · 3.2× alpha

0.3700

boldest claim

The sentences

a weak trendp=0.16not close (p > 0.1)

Patients with epigenetic mutations had a weak trend for higher response rates (62% vs 48%, p=0.16).

also in 1,404 other papers

showed a trendp=0.37not close (p > 0.1)

This difference remained significant for patients with ASXL1 mutations (n=29; survival 29 vs 12 months; p=0.026) while patients with mutations in EZH2 (n=12) showed a trend towards longer survival (20 vs 14 months; p=0.37).

also in 53,322 other papers

highly significantno p-value reported

This positive association was present in both cohorts and remained highly significant in the multivariate cox model.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.